Clinical evaluation of improved MyoSure hysteroscopic tissue removal system for the resection of type II submucosal myomas

Yufei Liang, BS, Yuefang Ren, MD, Zeqiu Wan, BS, Lihua Guo, BS, Jie Dong, MS, Yun Chen, BS, Liping Lv, BS*

Abstract
This study aims to determine whether clinical evaluation of improved MyoSure hysteroscopic tissue removal system can remove type II submucosal myomas with safety and high success rate of the first operation.

Fifty-three patients with type II submucosal myomas hospitalized in the Huzhou Maternity and Child Care Hospital were enrolled in this study. The submucosal myomas were with the diameter of >2 cm and ≤5 cm. All patients have surgical indications.

Fifty-one of 53 hysteromyomas were successfully resected through 1-time operation. The average time was 37.92 ± 18.57 minutes, average amount of bleeding: 24.80 ± 12.12 mL, average length of stay: 2.02 ± 0.14 days. One patient had a transient postoperative fever and one patient had slight fluid overload with hyponatremia.

The success rate of the first operation for resecting type II submucosal myomas showed an increase using improved MyoSure hysteroscopic tissue removal system, which can be a new, safer, and more efficient operation for treating type II submucosal myomas.

Abbreviations: FDA = The US Food and Drug Administration, FMM = The Free Myometrial Margin, GNRH-a = gonadotropin-releasing hormone agonist, MA = morcellator, SPSS = Statistic Package for Social Science, USA = The United States of America, XL = extra large.
Keywords: Hysteroscopy, leiomyoma, MyoSure

1. Introduction
Operative resection is a therapeutic option for submucosal myomas. Resection of hysterynomas instead of hysterectomy is a more commonly adopted therapy. The classic operative option for type II submucosal myomas is the warm soapsuds enema with electric resection, which requires skilled operators who have undergone massive training.[1] Therefore, the hysteroscopic electric resection cannot be performed in the low-grade hospitals. Meanwhile, the risk of electrothermal damage by electric resection is another concern. Hysteroscopic morcellator is a mechanical tissue removal system with the advantages of shorter operation time and less operative damage.[2,3] In 2005, the US Food and Drug Administration (FDA) approved the TRUCLEAR hysteroscopic morcellator (Smith & Nephew, MA) as the first mechanical morcellator for resecting intrauterine disease.[4] The MyoSure tissue removal system (Hologic, MA) was approved by FDA in 2009 and is more suitable as a hysteroscopic morcellator for treating intrauterine pathological lesions including submucosal myomas with the merits of rapid and easy operation and less complications. The operation of MyoSure is easier to be mastered compared with hysteroscopic electric resection. It was reported that the hysteroscopic morcellator was more rapid and easier compared with conventional electric resection.[5] No difference in terms of completeness was found between interns and senior surgeons,[4] which confirmed that the MyoSure system was easy to operate and suitable for the outpatient department and low-grade hospitals. Moreover, Rajesh and Guyer[6] reported that the MyoSure system could be safely used for removing submucosal myomas in an outpatient hysteroscopy setting, with satisfactory tolerance and nearly no complications. Also, the MyoSure system was successfully used for resecting endometrial polyps and types 0 and I submucosal myomas. However, the type II submucosal myomas were excluded in some previous studies[1,2,6,7] and the MyoSure system could not be used for type II submucosal myomas, as reported by Sardo et al.[5] Sardo et al reported some limitations for treating type II submucosal myomas using the MyoSure system: the success rate of the first operation was low, indicating the need for multiple operations or improved operation mode and the operative difficulty was high because 50% hysterynomas were embedded in the muscular layer leading to the risk of increased bleeding and liquid absorption.[8] The hysteromyomas in the muscular layer could be resected efficiently and safely if the hysteromyomas could be stripped off from the muscular layer and morcellated within the capsule using a new technique.[9] An apparatus was developed through clinical experience, which could accomplish incising, separating, and
clamping using the MyoSure system. Hysteromyomas embedded in the muscular layer could be stripped off into the uterine cavity under the direct vision of a hysteroscope using a combination of the invented apparatus and the MyoSure system, without altering intrauterine pressure or promoting uterine contraction by drugs. The type II submucosal myomas could be effectively removed by continuous morcellation of the MyoSure system. Thirty-two patients with type II submucosal myomas were treated using the improved MyoSure system in the present study. The data of medical records, hysteromyomas, and surgical operation of the patients were recorded and retrospectively analyzed.

2. Material and methods

2.1. Clinical information

The patients were admitted to the hospital between June 30, 2014 and June 30, 2016. The diagnosis of type II submucosal myomas was made in accordance with the criteria suggested by “Holland Haarlem International Hysteroscopic Training School” (no pedicle extending to the muscular layer >50%), and the diagnosis was confirmed by ultrasound examination, surgical operation and, pathological diagnosis. A total of 53 patients were recruited in this study. The surgeries were performed between day 2 and 7 after menstruation, and no contraindications were reported. The inclusion criteria were as follows: diagnosed as type II submucosal fibroids using preoperative ultrasound imaging with the largest diameter of fibroids ≥2 cm and ≤5 cm; the thickness of the myometrium (The Free Myometrial Margin-FMM-) between the myoma and the perimetrium had to at least 2 mm (preoperatively by ultrasound); presence of clinical symptoms which can affect life, or fibroids is considered to be the Only reason for infertility, the patient had a clear intention to surgery, and signed informed consent; without hysteroscopic surgery and anesthesia surgery contraindications. The exclusion criteria were: preoperative ultrasound imaging of fibroids with the largest diameter <2 cm or >5 cm; multiple fibroids; the FMM was 1<2 mm; pregnancy; the presence of female reproductive system of cancer pre-lesion or malignant disease; postmenopausal; pelvic inflammatory disease; preoperative use of GNRH-a or mifepristone; the patient refused to participate. All patients in this hospital were informed before surgery; all patients in this article were informed before surgery of the need to replace the surgical program, surgical costs, and surgical risk, and there may be a chance of secondary surgery. All patients signed the informed consent form and agree to use the relevant information for article writing and public publication. The current study was approved by the ethics committee of the Huzhou Maternity and Child Care Hospital (Zhejiang, China).

The data regarding the age, child-bearing history, abnormal menstruation, a history of abdominal surgery, and complications are listed in Table 1. All the hysteromyomas were solitary; their detailed information is listed in Table 2. The operation time, success rate of the first operation, amount of bleeding, length of stay, complications, abnormal menstruation, and its improvement and recovery are listed in Table 3.

The size of hysteromyomas was described by the maximum diameter. The submucosal myomas with the diameter of <2 cm could be removed through the uterine cervix directly after

### Table 1

| General information of patients (n=53) | 35.06 ± 12.72 |
|--------------------------------------|----------------|
| **Age**                              |                |
| Concurrent disease                   |                |
| Hypertension                         | 1              |
| Diabetes                             | 1              |
| Thyroid dysfunction                  | 0              |
| Psychosomatic disease                | 0              |
| Child-bearing history                |                |
| Previous Pregnancy                   | 40             |
| Never been pregnant                  | 13             |
| Abnormal menstruation                |                |
| Increased menstruation               | 36             |
| Prolonged menstruation               | 17             |
| Previous abdominal surgery†          |                |
| Cesarean section                     | 4              |
| Myomectomy                           | 6              |
| Appendectomy                         | 2              |
| Adnexal surgery                      | 3              |

| Table 2 |

| Data regarding hysteromyomas (n=53). |
|--------------------------------------|
| **Size of hysteromyomas, cm**       | 3.88 ± 1.39 |
| 2.0–3.0                              | 6            |
| 3.1–4.0                              | 23           |
| 4.1–5.0                              | 24           |
| Location of hysteromyomas in the uterus |
| Low segment                          | 6            |
| Middle segment                       | 32           |
| Bottom                               | 15           |
| Ratio between hysteromyomas located at the bottom of the uterus and those located in the uterine wall |
| ≤1/3                                 | 36           |
| >1/3–2/3                             | 12           |
| >2/3                                 | 5            |
| Expansion depth of the hysteromyoma into the muscular layer |
| ≥50%–60%                             | 32           |
| >60%–70%                             | 14           |
| >70%                                 | 7            |
| Distance between the margin of hysteromyomas and the uterine serosa, cm |
| >1                                   | 1            |
| 0.5–1.0                              | 25           |
| <0.5 cm                              | 27           |

† The size of the fibroids defaults to be the biggest diameter under B-ultrasoundography.

### Table 3

| Operation time, success rate of the first operation, bleeding amount, complications, and menstruation recovery (n=53). |
|---------------------------------------------------------------|
| **Operation time, min**                                       | 37.92 ± 18.57 |
| One-time resection                                            | 51            |
| Liquid loss amount, mL                                        | 503.40 ± 350.21 |
| amount of bleeding, mL                                        | 24.80 ± 12.12 |
| Complications                                                 |                |
| Uterine perforation                                           | 0             |
| Fluid overload with hyponatremia                             | 1             |
| Massive hemorrhage                                            | 0             |
| Transient fever                                               | 1             |
| Cervical laceration                                           | 0             |
| Recovered to normal*                                          |                |
| 3 Mo postoperatively                                          | 32            |
| 6 Mo postoperatively                                          | 44            |
| Length of stay, day                                           | 2.02 ± 0.14   |

† Refers to menstrual abnormalities returned to normal circumstances.
stripping off using the hysteroscope. Therefore, all the hystero-
yomyomas selected were with a diameter of >2 cm. The operation
success rate for hystero-myomas was reported to be correlated
with the size and number of hystero-myomas.\textsuperscript{[10]} The hyste-
ro-myomas with a diameter of >5 cm were pretreated with
gonadotropin-releasing hormone agonist (GnRH-a) before
operation to reduce the difficulty and postoperative complica-
tions.\textsuperscript{[11,12]} Hence, the hystero-myomas selected in this present
study were of \leq 5 cm in diameter.

\subsection*{2.2. Surgical operation personnel}
The operations were performed by the same chief obstetrician
and gynecologist under B-ultrasound surveillance by the same
chief imaging physician.

\subsection*{2.3. Indication of operation}
The indicators of operation included hystero-myomas with
menorrhagia or abnormal uterine bleeding; the size of the uterus
<10 weeks' gestation and uterine cavity <12 cm; maximum
diameter of hystero-myomas \leq 5 cm; no malignant lesion; patients
with strong request for uterus preservation; and hystero-myomas
as the only cause of infertility or recurrent abortion.

\subsection*{2.4. Preoperative preparation}
The patients were thoroughly informed of the potential surgical
risk and intraoperative or postoperative complications. The
complete preoperative examinations such as leucorrhea test,
blood cell counts, and serum biochemical examinations were
performed to exclude the inflammation of the genital tract. Drugs
or measures to soften the cervix were not required because the
cervix was expanded using a No. 6.5 cervical expander. The
patients were asked to fast for 6 hours before the operation and
not to drink for 4 hours before the operation.

\subsection*{2.5. Operative apparatus and instrument}
Normal saline was used as distention media (it was reported that
normal saline or lactated Ringer’s solution could reduce the risk
of liquid penetration) for all the patients. The automatic inflation
pump (Jingrui JG200, China) and the MyoSure hysteroscopic
tissue removal system (Hologic) were used; scissors, separators,
and grasping forceps were shown in Figures 1 and 2.

\subsection*{2.6. Anesthesia}
The general anaesthesia was performed.

\subsection*{2.7. Surgical operation}
The in-house made hysteroscopy apparatus was placed using the
MyoSure system and a uterus expansion pressure of 100 to 120
mm Hg, and the expansion pressure was not adjusted as long as
the operative vision was clear. The endometrium and capsule of
hystero-myomas were cut open using scissors. The hystero-my-
mas were stripped off into the uterine cavity using separators and
pliers, so that the type II submucosal myomas turned into type I
submucosal myomas and further morcellated within the capsule.
This step was repeated a few times to remove all the
hystero-myomas embedded in the muscular layer. The ultrasound
surveillance and monitoring was conducted by the same
physician. A complete removal surgery of tumor which the
tumor cannot be seen at original fibroids sites using B ultrasound imaging was thought to be a clean removal. The pathological examination confirmed all except one to be leiomyoma of the uterus; only one that failed to have a complete removal with 1-time operation was confirmed to be endometrioma (Fig. 3).

2.8. Observed parameters
The observed parameters included the operation time, success rate of the first operation, amount of bleeding, length of stay, complications, liquid loss amount (referred to the difference between uterine swelling liquid use, and the amount of uterine swelling liquid collected using collection bag coming out of the body), and menstruation improvement (Table 3).

2.9. Postoperative follow-up
Before discharge, patients were informed of the postoperative follow-up during 3 and 6 months after surgery, postoperative review of B-ultrasound in 3 months by the same doctor to check whether the original surgical site of tumor remains. And detailed records of patients with menstrual recovery to normal state of time were recorded.

2.10. Statistical analysis
All data were analyzed using SPSS 23 software (SPSS Inc, Chicago, IL).

3. Results
3.1. Baseline data
In this study, we included a total of 53 women with the type II submucosal myomas. Finally, 51 women completed the surgery and all the tumors were removed at one time (Fig. 4). Of the 2 patients who failed to achieve this, one was treated with GNRH-a for pathological diagnosis of adenomyosis and then Mirena Intrauterine Ring was placed and increased symptoms were observed; 1 case did not finish the surgery because of mild water poisoning, after 1-month hysteroscopic electrosurgical excision was performed to remove remaining tumor.

3.2. One-time complete resection rate
Fifty-one of 53 patients had the hysteromyomas completely resected with 1-time operation, with the success rate of 96.226%.

The average weight of the fibroids after weighed resuscitation was 31.47 ± 12.69g. Combined with intraoperative B-ultrasound images of the situation, we believe that 51 cases of patients were all one-time removal of the tumor, whereas the postoperative review of B-ultrasound in 3 months showed that beside the 3 patients lost, the remaining 49 patients showed no tumor remaining.

3.3. Operation time
The average whole operation time of 53 patients was 37.92 ± 18.57 minutes.

3.4. Bleeding amount
The average bleeding amount was 24.80 ± 12.12mL in 51 patients with successful 1-time operation. The mean hemoglobin was 93.61 ± 9.83g/L, whereas the average postoperative hemoglobin was 91.51 ± 9.61g/L. There was still some difference in hemoglobin before and after operation, but the visual field was relatively clearer and the operation could be completed successfully. Thus we thought that successful surgical bleeding amount was within the acceptable range. A typical feature in the case of a large hemorrhage is that the view is not clear, leading to a negative influence on surgical operation, increased complications, and perhaps multiple operations.

3.5. Average length of stay
The average length of stay was 2.02 ± 0.14 days. One patient in 51 patients who had a successful operation was hospitalized for 3 days because of fever. The remaining 50 patients were hospitalized for 2 days.

3.6. Complications
One patient (1/53) had a transient postoperative fever with the temperature of 37.7°C; the patient was discharged after 2 days of observation. The retrospective analysis did not reveal the cause of
fever, although it was reported that the transient fever was commonly found in the patients with severe anemia. One patient slight fluid overload with hyponatremia, and recovered after application of furosemidum. No uterine perforation was found in all 53 patients, although complications such as uterine perforation were found in the hysteroscopic morcellation treatment; no complication was related to the limited case number.

3.7. Postoperative follow-up

Two patients failed for the follow-up examination at 3 months postoperatively, and 3 patients failed for the examination at 6 months postoperatively. Postoperative review of B-ultrasound in 3 months showed that beside the 2 lost patients, all other 49 cases showed no tumor remains. The one who failed the complete removal with the first operation was intramuscularly injected with GNRH-a 6 times, and then the Mirena was placed. Another patient who did not have an 1-time resection received hysterectomy under the direct look under the shear, grasping, separation of the operation. Although the success rate of 1-time surgery reached 96.226%, but we still find some limitations, a patient suspended surgery owing to lack of liquid to 1250 mL and a slight water poisoning. One hysteromyoma had an indistinct boundary to the myometrium, and hence was difficult to strip off. The operation time was then prolonged with the liquid loss of 1000 mL. Therefore, the surgery was stopped, and the lesion was confirmed to be adenomyosis. Hence, attention should be paid to pathological types of lesion before the operation. Similarly, Arnold et al. reported that morcellation with the MyoSure system was unsuccessful in one woman with a calcified leiomyoma. The pathological type of the lesion could be determined by not only conventional ultrasound but also magnetic resonance imaging. Once the major part of the hysteromyoma was removed, the residual lesion with the maximum diameter of <2.0 cm could be stripped off completely into the uterine cavity using grasping forceps and removed using hysteroscopy. It not only increased the 1-time operation rate but also decreased the liquid usage, thus to minimize the fluid overload with the risk of hyponatremia.

Three months after operation, 2 cases were lost to follow-up. Of the 49 cases of successful operation, menstrual abnormalities of 32 cases disappeared and returned to normal. Six months after operation, 3 cases were lost to follow-up. Of the 48 cases of successful operation, menstrual abnormalities of 44 cases disappeared and returned to normal.

4. Discussion

The submucosal myomas usually result in abnormal uterine bleeding and are one of the major causes for organic intrauterine lesions. The endovascular therapy is not satisfactory for most submucosal myomas, and surgery is the commonly adopted treatment. The hysteroscopic electric resection is widely accepted for submucosal myomas; it has incomparable advantages over the conventional open-abdomen mode, and therefore it is regarded as a criterion standard treatment for submucosal myomas. However, hysteroscopic electric resection treatment is difficult for type II submucosal myomas among all kinds of submucosal myomas, with a higher risk of complications and need for skilled surgeons. Therefore, the hysteroscopic electric resection for type II submucosal myomas cannot be used in a low-grade hospital. Meanwhile, the endometrial damage caused by an electrothermal injury is another concern. The cold knife treatment under hysteroscopy is a currently developed therapeutic approach. It can maintain the anatomical and functional integrity of the myometrium without electrothermal damage. It is worthwhile to learn and master this new technology.

The MyoSure hysteroscopic tissue removal system has been recognized for treating types 0 and I submucosal myomas. However, it is not ideal for type II submucosal myomas with a lower rate of 1-time complete resection. A set of complementary hysteroscopic operating instruments was developed based on clinical experience. The low rate of 1-time complete resection for type II submucosal myomas could be improved by combining the new apparatus with the MyoSure system. Meanwhile, the advantages of the MyoSure system, including the efficiency and safety, were maintained.

More than 50% of type II submucosal fibroids were in the myometrium, and MyoSure cannot remove tumor in the muscle layer. We improved the laparoscopic surgical instruments, together with MyoSure which can be used on the basis of MyoSure under the direct look under the shears, grasping, separation of the operation. Although the success rate of 1-time surgery reached 96.226%, but we still find some limitations, a patient suspended surgery owing to lack of liquid to 1250 mL and a slight water poisoning. One hysteromyoma had an indistinct boundary to the myometrium, and hence was difficult to strip off. The operation time was then prolonged with the liquid loss of 1000 mL. Therefore, the surgery was stopped, and the lesion was confirmed to be adenomyosis. Hence, attention should be paid to pathological types of lesion before the operation. Similarly, Arnold et al. reported that morcellation with the MyoSure system was unsuccessful in one woman with a calcified leiomyoma. The pathological type of the lesion could be determined by not only conventional ultrasound but also magnetic resonance imaging. Once the major part of the hysteromyoma was removed, the residual lesion with the maximum diameter of <2.0 cm could be stripped off completely into the uterine cavity using grasping forceps and removed using hysteroscopy. It not only increased the 1-time operation rate but also decreased the liquid usage, thus to minimize the fluid overload with the risk of hyponatremia.
the operation. No placenta accreta or placenta adherens was reported in the former patient. However, more cases need to be explored to validate the pregnancy success after the resection of type II submucosal myomas using the improved MyoSure hysteroscopic tissue removal system.

Although the literatures reported that MyoSure hysteroscopic tissue removal system had a fast and safe advantage in resection of the intrauterine tissue, Meulenbroeks et al.9 reported that the TRUCLEAR system was significantly superior to MyoSure extra large (XL) in removing fibroids. When the larger fibroids are removed, the reduced durability of the MyoSure XL device may have an effect on the progression of the procedure, so if possible, the surgeon may choose the appropriate surgical instrument during surgery.

A B-ultrasound monitor was the standard equipment for difficult hysteroscopic operations. The noninvasiveness and real-time surveillance using B-ultrasound monitor can accurately estimate the residual myometrium thickness to compensate for the intraoperative visual defect.

But there is still another problem which is although the modified type of MyoSure system can improve the type II submucosal fibroids 1-time resection rate, but the cost still calls for our attention. The optical mirror and the accompanying instruments can be recycled after disinfection, but the operator required is non-repetitive and expensive, and the price was about 9000 yuan (around $1400), which certainly increased the burden of patients to a certain extent. Thus, we need to consider whether we should use modified MyoSure system to remove type II submucosal fibroids, and patient’s consent should be obtained before operation.

5. Conclusions

Besides cost problem the improved MyoSure hysteroscopic tissue removal system can improve the type II submucosal fibroids 1-time resection rate. It also maintained the advantages of the MyoSure system such as efficiency and high safety. This operation could preserve the uterus, ameliorate the symptoms of menorrhagia, and improve the life quality to a great extent. Given the limited case number in the present study, the complications, operation time, bleeding amount, postoperative menstrual improvement, and pregnancy using the improved MyoSure hysteroscopic tissue removal system need further validation using a larger number of cases.

Acknowledgment

The authors thank Dr. GAO Liwei, a surgeon from the Department of Surgery, Huzhou Hospital of Zhejiang University, for guidance on the manuscript.

References

[1] Emanuel MH, Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005;12:62-6.
[2] van Dongen H, Emanuel MH, Wolterbeek R, et al. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol 2008;15:466-71.
[3] AlHilli MM, Nixon KE, Hopkins MR, et al. Long-term outcomes after intrauterine morcellation vs hysteroscopic resection of endometrial polyps. J Minim Invasive Gynecol 2013;20:215-21.
[4] Arnold A, Kertheeswaran A, Bhatti M, et al. Prospective study on the use of the MyoSure(R) for hysteroscopic resection of endometrial pathology. J Minim Invasive Gynecol 2015;22:6s:545-6.
[5] Rajesh SK, Goyer C. MyoSure hysteroscopic morcellation for the management of submucous fibroids in an out-patient hysteroscopy setting. J Minim Invasive Gynecol 2015;22:6s:S102-3.
[6] Hamerlynck TW, Dietz V, Schoot BC. Clinical implementation of the hysteroscopic morcellator for removal of intrauterine myomas and polyps. A retrospective descriptive study, Gynecol Surg 2013;8:193-6.
[7] Di Spiezzo Sardo A, Mazzon I, Bramante S, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008;14:101-19.
[8] Haller JP. Single-stage total hysteroscopic myomectomies: indications, techniques, and results. Fertil Steril 1995;63:703-8.
[9] Loiffer FD. Removal of large symptomatic intrauterine growths by the hysteroscopic resectoscope. Obstet Gynecol 1990;76(3 pt 1):836-40.
[10] Hart R, Molnar BG, Magos A. Long-term follow up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol 1999;106:700-5.
[11] Donner J, Nisolle M, Grandjean P, et al. The place of GnRH agonists in the treatment of endometriosis and fibroids by advanced endoscopic techniques. Br J Obstet Gynaecol 1992;99(Suppl 7):S1-3.
[12] Tuífeckchiëva E, Nikolov A. Hystereosresction of submucous myomas after treatment with zoladex. Akush Ginekol (Sofia) 2006;45:19-24.
[13] Xia EL. Transcervical resectionof myoma. J Pract Obstet Gynecol 2003;21:387-9.
[14] Hamerlynck TW, Blikkendaal MD, Schoot BC, et al. An alternative approach for removal of placental remnants: hysteroscopic morcellation. J Minim Invasive Gynecol 2013;20:796-802.
[15] Cravello L, Agostini A, Belfi M, et al. Results of hysteroscopic myomectomy. Gynecol Obstet Fertil 2004;32:825-8.
[16] Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril 2000;73:1-4.
[17] Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol 2002;14:409-15.
[18] Mazzon I, Favilli A, Grasso M, et al. Is cold loop hysteroscopic myomectomy a safe and effective technique for the treatment of submucous myomas with intramural development? A series of 1434 surgical procedures. J Minim Invasive Gynecol 2013;22:792-8.
[19] Arnold A, Kertheeswaran A, Bhatti M, et al. A prospective analysis of hysteroscopic morcellation in the management of intrauterine pathologies. J Minim Invasive Gynecol 2016;23:435-41.
[20] Lasmar RR, Barroso PR, Dias R, et al. Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment—preliminary report J Minim Invasive Gynecol 2005;12:108-11.
[21] Propst AM, Liberman RF, Harlow BL, et al. Complications of hysteroscopic surgery: predicting patients at risk. Obstet Gynecol 2000;96:517-20.
[22] Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000;96:266-70.
[23] Leone FP, Calabrese S, Marciante C, et al. Feasibility and long-term efficacy of hysteroscopic myomectomy for myomas with intramural development by the use of non-electrical "cold" loops. Gynecol Surg 2012;9:155-61.
[24] Meulenbroeks D, Hamerlynck TW, Saglam-Kara S, et al. Hysteroscopic tissue removal systems: a randomized in vitro comparison. J Minim Invasive Gynecol 2017;24:159-64.